Investigation of the Safety and Feasibility of AAV1/SERCA2a Gene Transfer in Patients With Chronic Heart Failure
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine the safety and feasibility of giving an adeno-associated
viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a), driven by the
CMV promoter (AAV1-CMV-SERCA2a), to heart failure patients that have received a left
ventricular assist device (LVAD) for an accepted clinical indication.
Phase:
Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
British Heart Foundation Celladon Corporation Leducq Foundation